Shattuck Labs, Inc. (STTK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Shattuck Labs, Inc. (STTK) Healthcare & Pipeline Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology firm specializing in the development of innovative therapeutics for cancer and autoimmune diseases. With a focus on its lead product candidates in Phase 1 clinical trials, the company aims to address unmet medical needs in the oncology and immunology sectors.

What Is the Investment Thesis for STTK?

Shattuck Labs presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's ARC platform holds promise for developing novel immunotherapies, but its clinical programs are still in early stages. Key value drivers include the successful completion of Phase 1 trials for SL-172154 and SL-279252, which could lead to partnerships or further clinical development. The company's current market capitalization of $655M reflects the inherent uncertainty associated with early-stage biotech companies. A potential catalyst is the release of Phase 1 data, anticipated in late 2026 or early 2027, which could significantly impact the stock price. However, risks include clinical trial failures, regulatory hurdles, and the need for additional funding, potentially diluting existing shareholders. The company's negative profit margin of -4987.4% and gross margin of -82.0% highlight its reliance on external funding and the lack of revenue-generating products.

Based on FMP financials and quantitative analysis

STTK Key Highlights

Lead product candidate SL-172154 is in Phase 1 clinical trial for ovarian, fallopian tube, and peritoneal cancers, representing a potential near-term value driver.

• SL-279252, another key asset, is undergoing Phase 1 clinical trial for advanced solid tumors and lymphoma, expanding the company's therapeutic focus.
• The company's ARC platform offers a novel approach to immunotherapy, potentially differentiating it from competitors in the crowded oncology space.
• Shattuck Labs is headquartered in Austin, Texas, a growing hub for biotechnology innovation.
• The company has a relatively small team of 44 employees, indicating a lean operational structure.

Who Are STTK's Competitors?

STTK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STTK's Key Strengths?

Proprietary ARC platform technology.

• Early-stage clinical pipeline with novel immunotherapies.
• Experienced management team.
• Focus on unmet medical needs in cancer and autoimmune diseases.

What Are STTK's Weaknesses?

Early-stage clinical development with high risk of failure.

• Limited financial resources.
• Reliance on external funding.
• Lack of revenue-generating products.

What Could Drive STTK Stock Higher?

STTK catalyst: Release of Phase 1 clinical trial data for SL-172154 in ovarian, fallopian tube, and peritoneal cancers (expected late 2026 or early 2027).

• Initiation of Phase 2 clinical trials for SL-172154, contingent on positive Phase 1 results (potential 2027-2028).
• Release of Phase 1 clinical trial data for SL-279252 in advanced solid tumors and lymphoma (expected late 2026 or early 2027).
• Progress in developing new ARC molecules targeting other immune checkpoints and immunostimulatory receptors.
• Potential for strategic partnerships with larger pharmaceutical companies.

What Are the Key Risks for STTK?

Negative return on equity (-43.6%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for SL-172154 or SL-279252.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from established pharmaceutical companies and other biotech firms.
• Need for additional funding, potentially diluting existing shareholders.
• Economic downturn affecting funding for biotechnology companies.

What Are the Growth Opportunities for STTK?

• Expansion of SL-172154 Clinical Trials: Shattuck Labs has the opportunity to expand the clinical trials for SL-172154 to include other cancer types beyond ovarian, fallopian tube, and peritoneal cancers. This could significantly broaden the potential market for this drug candidate, addressing a larger patient population. The timeline for this expansion would depend on the results of the ongoing Phase 1 trial, with potential for new trials to commence in 2027. The market for broader CD40-targeted therapies is estimated to reach $5 billion by 2030.
• Advancement of SL-279252 Program: Successful completion of the Phase 1 trial for SL-279252 could pave the way for Phase 2 trials in specific lymphoma subtypes or solid tumors. This would represent a significant milestone for the company and could attract partnerships with larger pharmaceutical companies. The market for PD-1/4-1BB bispecific antibodies is projected to grow to $8 billion by 2032, offering substantial commercial potential for SL-279252.
• Development of New ARC Molecules: Shattuck Labs can leverage its ARC platform to develop additional drug candidates targeting other immune checkpoints and immunostimulatory receptors. This would diversify the company's pipeline and reduce its reliance on SL-172154 and SL-279252. The timeline for developing new ARC molecules is typically 2-3 years from discovery to IND filing. The market for novel immunotherapies is constantly evolving, with new targets emerging regularly.
• Strategic Partnerships and Licensing Agreements: Shattuck Labs can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements could provide upfront payments, milestone payments, and royalties, providing non-dilutive funding for the company. The timeline for securing partnerships is unpredictable, but typically occurs after positive Phase 1 or Phase 2 data. The value of licensing agreements varies widely depending on the stage of development and the market potential of the drug candidate.
• Expansion into Autoimmune Diseases: The ARC platform has potential applications beyond oncology, including autoimmune diseases. Shattuck Labs could explore developing ARC molecules targeting specific autoimmune pathways, such as TNF-alpha or IL-17. This would significantly expand the company's addressable market. The timeline for entering the autoimmune space would likely be 3-5 years, requiring preclinical studies and Phase 1 trials. The global autoimmune disease market is estimated to reach $150 billion by 2028.

What Are STTK's Competitive Advantages?

• Proprietary ARC platform technology: The company's ARC platform is a unique and patented technology that provides a competitive advantage in developing novel immunotherapies.
• Early-stage clinical pipeline: The company's lead product candidates are in Phase 1 clinical trials, representing a potential first-mover advantage in specific cancer and autoimmune disease indications.
• Experienced management team: The company's management team has extensive experience in drug development and commercialization.
• Strong intellectual property portfolio: The company has a strong intellectual property portfolio protecting its ARC platform and drug candidates.
• Strategic partnerships: Potential partnerships with larger pharmaceutical companies could provide access to funding, expertise, and commercialization infrastructure.

What Does STTK Do?

Shattuck Labs, Inc., founded in 2016 and headquartered in Austin, Texas, is a clinical-stage biotechnology company dedicated to pioneering new treatments for cancer and autoimmune diseases. The company's core strategy revolves around its proprietary Agonist Redirected Checkpoint (ARC) platform, which aims to develop bifunctional fusion proteins that simultaneously activate immunostimulatory receptors and block inhibitory receptors. This unique approach seeks to enhance the body's immune response against tumors while mitigating autoimmune reactions. Shattuck Labs' lead product candidate, SL-172154, is currently in Phase 1 clinical trials for the treatment of ovarian, fallopian tube, and peritoneal cancers. SL-172154 is designed to activate the CD40 receptor on immune cells, promoting anti-tumor activity. The company is also developing SL-279252, another ARC compound in Phase 1 clinical trials for advanced solid tumors and lymphoma. This molecule targets the PD-1/PD-L1 pathway, a well-established immune checkpoint, while also activating the 4-1BB receptor to stimulate T cell proliferation and survival. Shattuck Labs operates primarily in the United States, focusing on early-stage clinical development and strategic partnerships to advance its pipeline. The company's long-term vision is to establish itself as a leader in the field of bifunctional fusion proteins, delivering transformative therapies to patients with cancer and autoimmune disorders.

What Products and Services Does STTK Offer?

• Develops bifunctional fusion proteins using its Agonist Redirected Checkpoint (ARC) platform.
• Creates therapeutics for the treatment of cancer.
• Develops therapeutics for the treatment of autoimmune diseases.
• Conducts Phase 1 clinical trials for its lead product candidates.
• Focuses on activating immunostimulatory receptors and blocking inhibitory receptors.
• Aims to enhance the body's immune response against tumors.

How Does STTK Make Money?

• Develops and patents novel therapeutic molecules.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks partnerships with larger pharmaceutical companies for late-stage development and commercialization.
• Out-licenses its technology to other companies for specific applications.
• Potentially generates revenue through product sales upon regulatory approval.

What Industry Does STTK Operate In?

Shattuck Labs operates within the rapidly evolving biotechnology industry, specifically targeting the oncology and autoimmune disease markets. The global oncology market is projected to reach $400 billion by 2030, driven by an aging population and increasing cancer incidence. Immunotherapy, a key focus for Shattuck Labs, is a major growth area within oncology. The competitive landscape includes established pharmaceutical companies and numerous smaller biotech firms developing novel immunotherapies. Shattuck Labs aims to differentiate itself through its ARC platform, which combines immunostimulatory and checkpoint blockade mechanisms in a single molecule.

Who Are STTK's Key Customers?

• Patients with cancer.
• Patients with autoimmune diseases.
• Pharmaceutical companies seeking to license novel therapeutics.
• Healthcare providers who prescribe the company's drugs.
• Research institutions interested in collaborating on drug development.

Company Profile

Shattuck Labs, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Taylor H. Schreiber. STTK has traded publicly since 2020.

Shattuck Labs, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 39.80 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Shattuck Labs, Inc. stands at -43.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 27.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.5%, the inverse of the P/E and a quick read on earnings relative to price.

STTK Valuation & Market Position

With a $655M market cap, Shattuck Labs, Inc. sits in the small-cap segment of the market. Relative to its peer group, STTK's quantitative score of 24/100 is below the peer average of 76/100.

Shattuck Labs, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 6.3% above estimates on average.

Wall Street analysts project Shattuck Labs, Inc. revenue of about $1.6M for fiscal 2026, with EPS near $-0.48. The estimate reflects 8 contributing analysts.

STTK Financials

STTK Latest News

STTK Analyst Consensus

STTK MoonshotScore

STTK Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources